Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|10|1|46-54

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.10, Iss.1, 2010-02, pp. : 46-54

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma

By  

Current Drug Targets, Vol. 19, Iss. 5, 2018-03 ,pp. : 409-421

Bentham Science Publishers

Access to resources Recommend Favorite

Zoledronic Acid

By Cheer S.M.   Noble S.  

Drugs, Vol. 61, Iss. 6, 2001-01 ,pp. : 799-805

Adis International

Access to resources Recommend Favorite

Zoledronic acid

By Coleman Robert   Burkinshaw Roger   Winter Matthew   Neville-Webbe Helen   Lester Jim   Woodward Emma   Brown Janet  

Expert Opinion on Drug Safety, Vol. 10, Iss. 1, 2011-01 ,pp. : 133-145

Informa Healthcare

Access to resources Recommend Favorite

Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis

By Body Jean-Jacques  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 4, 2003-04 ,pp. : 567-580

Informa Healthcare

Access to resources Recommend Favorite

Can we Predict Disease Course with Clinical Factors?

By  

Current Drug Targets, Vol. 19, Iss. 7, 2018-04 ,pp. : 791-797

Bentham Science Publishers

Access to resources Recommend Favorite